Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease.
Amsterdam, Netherlands. In Alzheimers Dement, Feb 2016
Early changes were observed in levels of proteins related to cytoskeletal dynamics and synaptic components including an increase in RIMS1 and glutamate receptor, ionotropic kainate 4. Several synaptic proteins, such as BSN, LIN7A, DLG2, -3, and -4, exhibit an early-up, late-down expression pattern.
Modeling combined schizophrenia-related behavioral and metabolic phenotypes in rodents.
Townsville, Australia. In Behav Brain Res, 2015
In this review we focus on selected genetic (DBA/2J mice, leptin receptor mutants, and PSD-93 knockout mice), early neurodevelopmental (maternal protein deprivation) and pharmacological (acute phencyclidine) animal models that capture the combined behavioral and metabolic abnormalities shown by schizophrenic patients.
MAGUKs, synaptic development, and synaptic plasticity.
Bethesda, United States. In Neuroscientist, 2011
A major example of this is the neuronal synapse, which contains several presynaptic and postsynaptic MAGUKs including PSD-95, SAP102, SAP97, PSD-93, CASK, and MAGIs.
Research progress on neurobiology of neuronal nitric oxide synthase.
Nanjing, China. In Neurosci Bull, 2011
There are primarily 9 nNOS-interacting proteins, including post-synaptic density protein 95 (PSD95), clathrin assembly lymphoid leukemia (CALM), calcium/calmodulin-dependent protein kinase II alpha (CAMKIIA), Disks large homolog 4 (DLG4), DLG2, 6-phosphofructokinase, muscle type (PFK-M), carboxy-terminal PDZ ligand of nNOS (CAPON) protein, syntrophin and dynein light chain (LC).
Structure of the first PDZ domain of human PSD-93.
Copenhagen, Denmark. In Acta Crystallogr Sect F Struct Biol Cryst Commun, 2010
Comparison of the structures of the binding cleft of PSD-93 PDZ1 with the previously reported structures of PSD-93 PDZ2 and PDZ3 as well as of the closely related human PSD-95 PDZ1 shows that they are very similar in terms of amino-acid composition
Non-random inactivation of large common fragile site genes in different cancers.
Rochester, United States. In Cytogenet Genome Res, 2006
To determine if there was selection for the inactivation of different large CFS genes in different cancers, we examined the expression of 13 of the 20 known large CFS genes: FHIT, WWOX, PARK2, GRID2, NBEA, DLG2, RORA isoforms 1 and 4, DAB1, CNTNAP2, DMD, IL1RAPL1, IMMP2L and LARGE in breast, ovarian, endometrial and brain cancers using real-time RT-PCR analysis.